Looking for more information on the ongoing ADAPT Phase 3 clinical trial in MG? Click here.

Discovery programs

Using our SIMPLE Antibody™ technology, we have created libraries of specific antibodies against multiple and diverse targets of therapeutic relevance.

We continue to focus on novel, complex targets with functional involvement in cancer and severe autoimmune diseases.